BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

BDSI Products

Marketed Products

BDSI makes innovative therapies available.

BDSI offers a diverse portfolio of solutions for the treatment of chronic pain and other serious and debilitating chronic conditions.

Belbuca

BELBUCA®

BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA®) technology.

Contraindications
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to buprenorphine

For more information on BELBUCA® visit www.belbuca.com

Medication Guide Full Prescribing Information

SYMPROIC®

Symproic® (naldemedine) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

Contraindications
  • Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
  • Patients with a history of a hypersensitivity reaction to naldemedine

For more information on Symproic® visit www.symproic.com

Medication Guide Full Prescribing Information
Symprioc
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, 1-800-FDA-1088. Report an Adverse Event

BELBUCA®, BDSI®, and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. All other trademarks and trade names are the property of their respective owners.

Recent BDSI News

September 11, 2020

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients

Read more
September 3, 2020

RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive

Read more
August 5, 2020

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 19, 2020BDSI $3.52/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.